The History of the NCI at Frederick

  1. 1971

    National Cancer Act Signed

    President Richard Nixon signed the National Cancer Act on December 23, 1971, calling it a “national commitment for the conquest of cancer.” This became popularly known as the “war on cancer.” The act expanded federal funding for cancer research and created the National Cancer Institute in Frederick, part of the National Institutes of Health under what is now known as the Department of Health and Human Services.

  2. 1972

    68 acres and 67 buildings of the U.S. Army were designated to be transferred to HHS.

    This executive order shut down the biowarfare operations at Fort Detrick and turned the property that housed those operations over to the U.S. Department of Health and Human Services for cancer research.

  3. 1975

    NCI received FFRDC designation for the Frederick location.

    The National Science Foundation notified DHHS that the Frederick facility met the criteria for and was designated as a Federally Funded Research and Development Center (FFRDC).

  4. 1976

    Official Transfer of Land and Buildings from DOD to NCI

    All buildings and acreage being used by NCI were formally transferred from the Department of Defense and Department of the Army to DHHS and the National Institutes of Health.

  5. 1982

    NCI divides into five functional components.

    NCI divided the existing, single contractor into five components: Basic Research, Operations and Technical Support, Animal Production, Computer Services, and the Scientific Library.

  6. 1984

    FNLCR helped develop and manufacture an HIV/AIDS test on large-scale for national use.

  7. 1993

    Biopharmaceutical Development Program (BDP) is developed

    BDP supports the development of monoclonal antibodies, recombinant proteins, therapeutic peptides and DNA vaccines, oligonucleotides, virus therapeutics and vaccines, gene therapy products, and other biological agents.

  8. 2003

    Nanotechnology Characterization Laboratory developed for accelerating nanotechnology research

    The National Cancer Institute established the Nanotechnology Characterization Laboratory (NCL) as a collaboration with the National Institute of Standards and Technology and the Food and Drug Administration. The NCL conducts preclinical characterization and toxicity testing on nanomaterials that have been developed in academic, government, and commercial laboratories to diagnose and treat cancer.

  9. 2005

    HPV Immunology Laboratory worked in support of the development of a cervical cancer vaccine used for clinical trials and used nationwide.

  10. 2010

    The Biopharmaceutical Development Program (BDP) assisted in the development of ch14.18 and manufactured doses of the immunotherapy for clinical testing in children with neuroblastoma, the most common cancer affecting infants.

  11. 2013

    ACVP collaborates with OHSU to discover vaccine-associated immune clearance

    Jeff Lifson and colleagues in the AIDS and Cancer Virus Program, working in collaboration with Louis Picker (Oregon Health & Science University), demonstrate vaccine-associated immune clearance of infection in a nonhuman primate AIDS virus infection model.